

PATENT & TRADEMARK OFFICE  
FILING RECEIPT

\*OC00000005062353\*

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/500,162	02/08/2000	1643	598	08523/006002	14	20	5

Kristina Bieker-Brady  
 Clark & Elbing LLP  
 176 Federal Street  
 Boston, MA 02110

RECEIVED

APR 24 2000

CLARK & ELBING LLP  
 Date Mailed: 04/19/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Judes Poirier, Boisbriand, CANADA;

**Continuing Data as Claimed by Applicant**

THIS APPLICATION IS A CON OF 08/766,975 12/16/1996 PAT 6,022,683

**Foreign Applications****If Required, Foreign Filing License Granted 04/19/2000****\*\* SMALL ENTITY \*\*****Title**

Pharmacogenetic methods for use in the treatment of nervous system diseases

**Preliminary Class**

514

**Data entry by : MAY, MOLIKI****Team : OIPE****Date: 04/19/2000**

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
 Office of Initial Patent Examination  
 Customer Service Center  
 Washington, DC 20231



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



CONFIRMATION NO. 2201

Bib Data Sheet

SERIAL NUMBER 09/500,162	FILING DATE 02/08/2000 RULE	CLASS 435	GROUP ART UNIT 1648	ATTORNEY DOCKET NO. 08523/006002
-----------------------------	-----------------------------------	--------------	------------------------	--

## APPLICANTS

Judes Poirier, Boisbriand, CANADA;

## \*\* CONTINUING DATA \*\*\*\*

This application is a CON of 08/766,975 12/16/1996 PAT 6,022,683  
and is a CIP of 08/727,637 02/21/1997 PAT 5,935,781  
which is a 371 of PCT/CA95/00240 04/26/1995

## \*\* FOREIGN APPLICATIONS \*\*\*\*

## IF REQUIRED, FOREIGN FILING LICENSE GRANTED \*\* SMALL ENTITY \*\*

\*\* 04/19/2000

Foreign Priority claimed	<input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR	SHEETS	TOTAL	INDEPENDENT
35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance	COUNTRY	DRAWING	CLAIMS	CLAIMS
Verified and Acknowledged	Examiner's Signature Initials	CANADA	14	20	5

## ADDRESS

21559  
CLARK & ELBING LLP  
101 FEDERAL STREET  
BOSTON, MA  
02110

## TITLE

Pharmacogenetic methods for use in the treatment of nervous system diseases

FILING FEE	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue )
RECEIVED 598		



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 2201

SERIAL NUMBER 09/500,162	FILING DATE 02/08/2000 RULE	CLASS 435	GROUP ART UNIT 1648	ATTORNEY DOCKET NO. 08523/006002
<b>APPLICANTS</b> Judes Poirier, Boisbriand, CANADA;				
<b>** CONTINUING DATA *****</b> This application is a CON of 08/766,975 12/16/1996 PAT 6,022,683 and is a CIP of 08/727,637 02/21/1997 PAT 5,935,781 which is a 371 of PCT/CA95/00240 04/26/1995				
<b>** FOREIGN APPLICATIONS *****</b>				
<b>IF REQUIRED, FOREIGN FILING LICENSE GRANTED** SMALL ENTITY **</b> ** 04/19/2000				
Foreign Priority claimed 35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY CANADA	SHEETS DRAWING 14	TOTAL CLAIMS 20
Verified and Acknowledged Examiner's Signature _____ Initials _____	INDEPENDENT CLAIMS 5			
<b>ADDRESS</b> Kristina Bieker-Brady Clark & Elbing LLP 176 Federal Street Boston, MA 02110				
<b>TITLE</b> Pharmacogenetic methods for use in the treatment of nervous system diseases				
FILING FEE RECEIVED 598	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		

APPLICATION NUMBER	FILING DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO
09/500,162	02/08/2000	435	1648	08523/006002

APPLICANT  
JUDES POIRIER, BOISBRIAND, CANADA.

\*\*CONTINUING DOMESTIC DATA\*\*\*\*\*  
VERIFIED THIS APPLN IS A CON OF 08/766,975 12/16/1996 PAT 6,022,683 -NON-AD  
WHICH IS A CIP OF 08/727,637 10/16/1996 -AD ONLY  
WHICH IS A NAT. STAGE OF PCT/CN96/00240 on 8/6/95 -AD ONLY

\*\*371 (NAT'L STAGE) DATA\*\*\*\*\*  
VERIFIED

\*\*FOREIGN APPLICATIONS\*\*\*\*\*  
VERIFIED

FOREIGN FILING LICENSE GRANTED 04/19/2000 SMALL ENTITY

Foreign priority claimed 35 USC 119 (a-d) conditions met	<input type="radio"/> yes <input type="radio"/> no <input type="radio"/> yes <input type="radio"/> no <input type="radio"/> Met after Allowance	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
Verified and acknowledged _____	Examiner's Name _____ Initials _____	CAX	14	25	5

ADDRESS Kristina Bieker-Brady Clark & Elbing LLP 176 Federal Street Boston , MA 02110	
---	--

TITLE PHARMACOGENETIC METHODS FOR USE IN THE TREATMENT OF NERVOUS SYSTEM DIS EASES	
--	--

FILING FEE RECEIVED  \$*****0	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT NO. _____ for the following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of Time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
--	---	--